At Locust Walk, we are often tasked with addressing complex strategic business issues for our biopharma clients. Perhaps one of the most common dilemmas is how best to optimize a given company’s clinical development strategy to maximize value.
Term sheet negotiations are rarely easy, and there are multiple ways negotiations can break down before a deal is reached.
Having lived in Japan for more than 20 years, I have admittedly become perhaps a little too accustomed to the Japanese lifestyle. This is probably why after a few days in the hustle and bustle of Shanghai
Emerging biopharma companies with promising lead candidates in late-stage trials are often faced with a fundamental decision: go-it-alone (self-commercialize) or secure a strategic partner to support development and commercialization.
The JP Morgan Healthcare Conference, or “JPM”, is the healthcare conference of the year. Companies from all over the world convene in San Francisco to setup meetings with investors
CATEGORIES News Events Publications ARCHIVE We’re All Heart: Best in Show at TCT It is that time of year again
Besides calling the Ghostbusters, how does one catch a ghost? That is the question asked by most life science companies trying to raise capital from family offices
For many years, the fundraising environment for MedTech companies has been exceedingly difficult. Venture firms that were historically active in MedTech shifted their investment allocations to other areas of life sciences and capital became constrained.
Raising capital for an emerging biotech company is rarely easy. Tremendous time and effort goes into crafting the perfect story, determining the amount of capital you need to raise and what that money will be used for and reaching out to investors.
Though often overlooked or made by default, decisions about the structure and timing of a competitive deal process can have a significant impact on the ultimate value realized by the sell-side company.